Browse RNF212

Summary
SymbolRNF212
Namering finger protein 212
Aliases FLJ38841; LOC285498; hypothetical protein LOC285498; ZHP3; Probable E3 SUMO-protein ligase RNF212
Chromosomal Location4p16.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus Chromosome Note=Associates to the synaptonemal complex. Localizes to a minority of double-strand breaks (DSBs) sites. Marks crossover sites during midpachynema (By similarity).
Domain PF14634 zinc-RING finger domain
Function

SUMO E3 ligase that acts as a regulator of crossing-over during meiosis: required to couple chromosome synapsis to the formation of crossover-specific recombination complexes. Localizes to recombination sites and stabilizes meiosis-specific recombination factors, such as MutS-gamma complex proteins (MSH4 and MSH5) and TEX11. May mediate sumoylation of target proteins MSH4 and/or MSH5, leading to enhance their binding to recombination sites. Acts as a limiting factor for crossover designation and/or reinforcement and plays an antagonist role with CCNB1IP1/HEI10 in the regulation of meiotic recombination (By similarity).

> Gene Ontology
 
Biological Process GO:0006310 DNA recombination
GO:0006311 meiotic gene conversion
GO:0007059 chromosome segregation
GO:0007126 meiotic nuclear division
GO:0007127 meiosis I
GO:0007129 synapsis
GO:0007131 reciprocal meiotic recombination
GO:0016925 protein sumoylation
GO:0018205 peptidyl-lysine modification
GO:0035822 gene conversion
GO:0035825 reciprocal DNA recombination
GO:0045132 meiotic chromosome segregation
GO:0045143 homologous chromosome segregation
GO:0051026 chiasma assembly
GO:0051321 meiotic cell cycle
GO:0070192 chromosome organization involved in meiotic cell cycle
GO:0098813 nuclear chromosome segregation
GO:1903046 meiotic cell cycle process
Molecular Function GO:0016874 ligase activity
Cellular Component GO:0000793 condensed chromosome
GO:0000794 condensed nuclear chromosome
GO:0000795 synaptonemal complex
GO:0044454 nuclear chromosome part
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolRNF212
Namering finger protein 212
Aliases FLJ38841; LOC285498; hypothetical protein LOC285498; ZHP3; Probable E3 SUMO-protein ligase RNF212
Chromosomal Location4p16.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between RNF212 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolRNF212
Namering finger protein 212
Aliases FLJ38841; LOC285498; hypothetical protein LOC285498; ZHP3; Probable E3 SUMO-protein ligase RNF212
Chromosomal Location4p16.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of RNF212 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolRNF212
Namering finger protein 212
Aliases FLJ38841; LOC285498; hypothetical protein LOC285498; ZHP3; Probable E3 SUMO-protein ligase RNF212
Chromosomal Location4p16.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of RNF212 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.0870.703
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.2320.621
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.0160.966
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.5340.405
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-1.0740.381
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.1420.918
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.0670.933
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15111.0230.394
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-1.0550.397
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.1960.838
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.5210.681
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.6760.00733
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of RNF212 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27737.42.74.70.294
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27597.43.440.587
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211705.9-5.90.447
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131109.1-9.10.458
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91606.2-6.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolRNF212
Namering finger protein 212
Aliases FLJ38841; LOC285498; hypothetical protein LOC285498; ZHP3; Probable E3 SUMO-protein ligase RNF212
Chromosomal Location4p16.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of RNF212. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolRNF212
Namering finger protein 212
Aliases FLJ38841; LOC285498; hypothetical protein LOC285498; ZHP3; Probable E3 SUMO-protein ligase RNF212
Chromosomal Location4p16.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of RNF212. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by RNF212.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolRNF212
Namering finger protein 212
Aliases FLJ38841; LOC285498; hypothetical protein LOC285498; ZHP3; Probable E3 SUMO-protein ligase RNF212
Chromosomal Location4p16.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of RNF212. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolRNF212
Namering finger protein 212
Aliases FLJ38841; LOC285498; hypothetical protein LOC285498; ZHP3; Probable E3 SUMO-protein ligase RNF212
Chromosomal Location4p16.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of RNF212 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolRNF212
Namering finger protein 212
Aliases FLJ38841; LOC285498; hypothetical protein LOC285498; ZHP3; Probable E3 SUMO-protein ligase RNF212
Chromosomal Location4p16.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between RNF212 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolRNF212
Namering finger protein 212
Aliases FLJ38841; LOC285498; hypothetical protein LOC285498; ZHP3; Probable E3 SUMO-protein ligase RNF212
Chromosomal Location4p16.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting RNF212 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.